Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;47(10):1531-1538.
doi: 10.1111/jcpt.13697. Epub 2022 Jul 22.

Benefit of medication reviews by renal pharmacists in the setting of a computerized physician order entry system with clinical decision support

Sarah Seiberth  1   2 , Hanna Mannell  2 , Christof Birkenmaier  3 , Carl Neuerburg  3 , Vera Smolka  3 , Monika Andraschko  1 , Dorothea Strobach  1   2
Affiliations

Benefit of medication reviews by renal pharmacists in the setting of a computerized physician order entry system with clinical decision support

Sarah Seiberth et al. J Clin Pharm Ther. 2022 Oct.

Abstract

What is known and objective: A 'renal pharmacist consultant service' (RPCS) reviewing patients' charts with renal impairment (RI) for drug-related problems (DRP) can foster patient safety. However, the benefit of this service in the new setting of a computerized physician order entry (CPOE)-system with a clinical decision support (CDS)-system is unknown. The aim of our study was to evaluate the general need for an RPCS on wards with a CPOE-CDS-system already in use and its effectiveness on prescription changes to ensure in-hospital patient safety.

Methods: Over a period of 3 months (02-04/2021), elective orthopaedic and trauma patients with eGFRabsolute /CrCl <60 ml/min at a German University Hospital received a medication review by a renal pharmacist for all medication entered into the CPOE-system (Meona®) by the treating physicians. Written consultations explaining identified DRP and recommending interventions to solve them, for example, dose or drug adaptation, were shared with the physicians directly in the drug chart tab of Meona®. In complex cases, DRP were additionally discussed via phone. The prescription changes were evaluated retrospectively.

Results and discussion: During 53 working days, 712 (30.5%) of 2331 screened patients were included with an eGFRnon-indexed /CrCl <60 ml/min and a pharmacist-led medication review was performed for all medication presented in the CPOE-system (Meona®). In 79 of 712 (11.1%) patients, one or more DRP were detected (median 1 DRP (1-3) per patient) and written recommendations concerning 106 of 1090 (9.7%) drugs were shared via Meona®. In total, 104 DRP were identified, mostly caused by 'dosage too high' (n = 55, 52.9%), 'dosage regime wrong' (n = 13, 12.5%), and 'contraindication' (n = 9, 8.7%). Acceptance rate of recommendations was 74.0% (n = 77/104). In nine cases (8.7%), despite of specific recommendations, no adjustment of drugs was made because of lack of alternatives. In 11 (10.6%) cases, prescription remained unchanged for unknown reasons and in seven (6.7%) cases, the result was unknown due to discharge.

What is new and conclusion: In the setting of prescribing in a CPOE-CDS-system, that provides physicians with advice for drug or dose adaption, the pharmacist-led medication reviews still identified DRP in orthopaedic and trauma patients with RI. A RPCS forwarding recommendations to solve DRP via the electronic medical record increased appropriate prescribing by physicians and, thus, may further improve patient safety.

Keywords: CPOE-CDS-system; drug-related problems; pharmacist-led medication review; renal impairment; renal pharmacist.

PubMed Disclaimer

References

REFERENCES

    1. Kielstein J, Keller F. Pharmakotherapie bei Patienten mit chronischer Nierenkrankheit. Der Internist. 2012;53:802-809.
    1. Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Deutsches Arzteblatt Int. 2010;107:647-655.
    1. Blix HS, Viktil KK, Moger TA, et al. Use of renal risk drugs in hospitalized patients with impaired renal function-an underestimated problem? Nephrol Dial Transplant. 2006;21:3164-3171. doi:10.1093/ndt/gfl399
    1. Seiberth S, Bauer D, Schönermarck U, et al. Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission. Eur J Clin Pharmacol. 2020;76:1683-1693. doi:10.1007/s00228-020-02953-6
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.

LinkOut - more resources